French Ministry of Health prospective multicentre study using bio-active stents coated with titanium nitride oxide: the EVIDENCE registry

Autor: Frederic Collet, Bernard Karsenty, Christophe Loubeyre, Antoine Gommeaux, Paul Barragan, Patrick Dupouy, Olivier Wittenberg, Gérard Finet, Philippe Durand, Xavier Tabone, Jean Fajadet, Thierry Unterseeh, Pierre Meyer, Marie-Claude Morice, Marc Silvestri, Benoit Gerardin, Simon Cattan, Michael Angioi, Jean-Marc Lablanche, Marc-Éric Moulichon, Smain Sayah
Rok vydání: 2011
Předmět:
Male
Percutaneous
Time Factors
Stents bio-actifs
medicine.medical_treatment
Native coronary arteries
Myocardial Infarction
Coronary Angiography
Severity of Illness Index
Government Agencies
Coated Materials
Biocompatible

Clinical endpoint
Myocardial infarction
Prospective Studies
Registries
Angioplasty
Balloon
Coronary

Outcome
Aged
80 and over

Titanium
Résultat clinique
Incidence (epidemiology)
Bioactive stents
General Medicine
Middle Aged
medicine.anatomical_structure
Treatment Outcome
Drug Therapy
Combination

Female
Stents
France
medicine.symptom
Cardiology and Cardiovascular Medicine
Artery
medicine.medical_specialty
Prosthesis Design
Lesion
medicine
Humans
cardiovascular diseases
Aged
business.industry
Coronary Stenosis
Artères coronaires natives
Stent
Thrombosis
equipment and supplies
medicine.disease
Surgery
Titanium-nitride-oxide
business
Platelet Aggregation Inhibitors
Zdroj: Archives of cardiovascular diseases. 105(2)
ISSN: 1875-2128
Popis: Summary Background Coronary stents have evolved over time, from bare-metal stents to drug-eluting stents, and now to bioactive stents. Aims We sought to explore the immediate outcome of the titanium-nitride-oxide-coated bioactive stent, Titan2 ® , in real-world practice, and the incidence of major cardiac events at follow-up. Methods Consecutive patients admitted for percutaneous intervention for at least one significant (≥ 50%) lesion in a native coronary artery were treated with Titan2 ® stent implantation. The primary endpoint was total major adverse cardiac events at 12-month follow-up. Secondary endpoints included target lesion revascularization at 12-month follow-up and the duration of dual antiplatelet therapy. Results Among 356 patients (mean age 67.4 ± 12.1 years), 77.2% were male and 39.3% were treated for myocardial infarction (MI). A total of 546 Titan2 ® stents were implanted in 420 lesions. Angiographic and clinical procedural success was achieved in all cases. No cases of in-hospital major adverse cardiac events or acute stent thrombosis were reported. Of 335 patients (94.1%) with 12-month clinical follow-up, four (1.2%) died, MI occurred in five (1.5%), target lesion revascularization was performed in 17 (5.1%) and major adverse cardiac events occurred in 24 (7.2%). One patient (0.3%) suffered late stent thrombosis during follow-up, but no cases of acute or subacute stent thrombosis occurred. Dual antiplatelet therapy continued beyond 6 months in 64.5% of patients. Conclusions In real-world practice, Titan2 ® stent implantation achieves an excellent immediate outcome, with a low incidence of major adverse cardiac events at 12-month follow-up.
Databáze: OpenAIRE
Pro tento záznam nejsou dostupné žádné jednotky.